Abstract
Neuropathic pain (NP) is a sustained and nonreversible condition characterized by long-term devastating physical and psychological damage. Therefore, it is urgent to identify an effective treatment for NP. Unfortunately, the precise pathogenesis of NP has not been elucidated. Currently, the microbiota-gut-brain axis has drawn increasing attention, and the emerging role of gut microbiota is investigated in numerous diseases including NP. Gut microbiota is considered as a pivotal regulator in immune, neural, endocrine, and metabolic signaling pathways, which participates in forming a complex network to affect the development of NP directly or indirectly. In this review, we conclude the current understanding of preclinical and clinical findings regarding the role of gut microbiota in NP and provide a novel therapeutic method for pain relief by medication and dietary interventions.
Introduction
Neuropathic pain (NP) is a debilitating condition resulting from lesions or diseases affecting the somatosensory system. Unlike acute pain, NP is often chronic, nonreversible, and notoriously resistant to conventional painkillers. While researchers have long focused on peripheral and central sensitization, the underlying drivers of these processes remain partially obscured. This paper explores the role of the gut microbiota—the trillions of microbes residing in our digestive tract—as a critical, bidirectional regulator of NP through the microbiota-gut-brain axis.
Methods
This review synthesizes findings from a comprehensive systematic search of literature published between 2000 and 2020. The analysis focuses on signaling pathways—metabolic, neural, immune, and endocrine—that connect the gut to pain perception. It aggregates data from preclinical animal models, such as germ-free mice and various nerve injury models (SNI, PNI), alongside available clinical observations involving probiotics, fecal microbiota transplantation (FMT), and dietary interventions.
The Microbiota-Gut-Brain Axis
The communication between the gut and the central nervous system (CNS) involves a complex network of pathways including the vagus nerve, spinal pathways, and systemic circulation. Gut microbiota acts as a pivotal regulator in these systems, influencing the development of NP both directly and indirectly.
Key Mechanisms of Pain Modulation
The interaction between microbes and pain can be categorized into four primary modules:
- Immune Modulation: Microbes release Pathogen-Associated Molecular Patterns (PAMPs), such as Lipopolysaccharides (LPS), which activate Toll-like receptors (specifically TLR4) on immune cells. This triggers a cascade of pro-inflammatory cytokines (TNF-α, IL-1β) that directly sensitize nociceptors.
- Neurotransmitter Synthesis: Certain gut bacteria, such as Escherichia coli and Lactobacillus, can synthesize neurotransmitters like GABA (inhibitory) or influence Serotonin (5-HT) production, affecting descending pain modulation.
- Remote Glial Activation: Gut-derived metabolites like Short-Chain Fatty Acids (SCFAs) can signal through the vagus nerve or cross the blood-brain barrier to activate microglia and astrocytes in the spinal cord, sustaining neuroinflammation.
- Endocrine Connection: Gut hormones like GLP-1 and PYY, regulated by microbial activity, have demonstrated anti-nociceptive effects.
Therapeutic Strategies and Results
Targeting the gut-brain axis presents several promising therapeutic avenues:
- Probiotics: Specific strains, such as Lactobacillus fermentum, increase anti-inflammatory cytokines like IL-10, effectively reducing mechanical hyperalgesia in animal models.
- Fecal Microbiota Transplantation (FMT): Clinical cases have shown significant recovery in patients with fibromyalgia following FMT, suggesting that "resetting" the microbiome can have profound systemic effects.
- Dietary Intervention: Low-FODMAP diets may reduce LPS levels, lowering systemic inflammation and alleviating "bottom-up" pain signaling.
- Vitamin D: Supplementation helps maintain the intestinal barrier, preventing "leaky gut" and the translocation of pain-triggering microbial products into the bloodstream.
Limitations and Future Directions
Translating these insights into clinical practice faces several hurdles. The exact causal microbial profiles remain elusive, and most evidence currently stems from rodent models. Furthermore, the high degree of individual variability in the microbiome necessitates a move toward personalized microbial medicine. Future research should focus on identifying specific microbial biomarkers for NP and conducting large-scale, randomized controlled trials to validate gut-targeted therapies.
Summary updated